ScoreWhy is Gland Pharma Ltd ?
1
Company has a low Debt to Equity ratio (avg) at 0 times
2
Poor long term growth as Operating profit has grown by an annual rate -6.65% of over the last 5 years
3
Flat results in Sep 25
- PBT LESS OI(Q) At Rs 199.76 cr has Fallen at -14.8% (vs previous 4Q average)
- DEBTORS TURNOVER RATIO(HY) Lowest at 0.37 times
4
With ROE of 8.3, it has a Expensive valuation with a 3.1 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of -2.87%, its profits have risen by 14.3% ; the PEG ratio of the company is 2.6
5
High Institutional Holdings at 40.54%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
6
Consistent Underperformance against the benchmark over the last 3 years
- Along with generating -2.87% returns in the last 1 year, the stock has also underperformed BSE500 in each of the last 3 annual periods
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Gland Pharma should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Gland Pharma for you?
Medium Risk, Low Return
Absolute
Risk Adjusted
Volatility
Gland Pharma
27.05%
-0.11
27.18%
Sensex
-4.95%
0.44
11.83%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
13.18%
EBIT Growth (5y)
0.04%
EBIT to Interest (avg)
96.17
Debt to EBITDA (avg)
0.15
Net Debt to Equity (avg)
-0.30
Sales to Capital Employed (avg)
0.58
Tax Ratio
29.86%
Dividend Payout Ratio
42.46%
Pledged Shares
0
Institutional Holding
40.65%
ROCE (avg)
20.24%
ROE (avg)
10.76%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
35
Industry P/E
34
Price to Book Value
3.50
EV to EBIT
27.50
EV to EBITDA
20.35
EV to Capital Employed
4.55
EV to Sales
5.16
PEG Ratio
0.70
Dividend Yield
0.82%
ROCE (Latest)
16.56%
ROE (Latest)
10.09%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
Bearish
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend19What is working for the Company
NET SALES(Q)
Highest at Rs 1,742.79 cr
PBDIT(Q)
Highest at Rs 513.02 cr.
OPERATING PROFIT TO NET SALES(Q)
Highest at 29.44%
PBT LESS OI(Q)
Highest at Rs 394.33 cr.
PAT(Q)
Highest at Rs 366.68 cr.
EPS(Q)
Highest at Rs 22.25
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...
Here's what is working for Gland Pharma
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 394.33 cr has Grown at 54.2% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 255.65 CrMOJO Watch
Near term PBT trend is very positive
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
At Rs 366.68 cr has Grown at 69.6% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 216.19 CrMOJO Watch
Near term PAT trend is very positive
PAT (Rs Cr)
Net Sales - Quarterly
Highest at Rs 1,742.79 cr
in the last five quartersMOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Operating Profit (PBDIT) - Quarterly
Highest at Rs 513.02 cr.
in the last five quartersMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (Rs Cr)
Operating Profit Margin - Quarterly
Highest at 29.44%
in the last five quartersMOJO Watch
Company's efficiency has improved
Operating Profit to Sales
Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 394.33 cr.
in the last five quartersMOJO Watch
Near term PBT trend is positive
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
Highest at Rs 366.68 cr.
in the last five quartersMOJO Watch
Near term PAT trend is positive
PAT (Rs Cr)
Earnings per Share (EPS) - Quarterly
Highest at Rs 22.25
in the last five quartersMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (Rs)
Here's what is not working for Gland Pharma
Non Operating Income - Quarterly
Highest at Rs 111.47 cr
in the last five quartersMOJO Watch
Increased income from non business activities may not be sustainable
Non Operating Income
